Neuronal accumulation and spread of pathological α-synuclein (α-syn) fibrils are key events in Parkinson's disease (PD) pathophysiology. However, the neuronal mechanisms underlying the uptake of α-syn fibrils remain unclear. In this work, we identified as a PD risk gene that affects α-syn aggregation. Overexpressing FAM171A2 promotes α-syn fibril endocytosis and exacerbates the spread and neurotoxicity of α-syn pathology. Neuronal-specific knockdown of FAM171A2 expression shows protective effects. Mechanistically, the FAM171A2 extracellular domain 1 interacts with the α-syn C terminus through electrostatic forces, with >1000 times more selective for fibrils. Furthermore, we identified bemcentinib as an effective blocker of FAM171A2-α-syn fibril interaction with an in vitro binding assay, in cellular models, and in mice. Our findings identified FAM171A2 as a potential receptor for the neuronal uptake of α-syn fibrils and, thus, as a therapeutic target against PD.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1126/science.adp3645 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Phosphorylation-Induced Self-Coacervation versus RNA-Assisted Complex Coacervation of Tau Proteins.
J Am Chem Soc
March 2025
Institute of Biological Chemistry, Academia Sinica, No. 128, Sec. 2, Academia Road, Nankang, Taipei 115, Taiwan.
In this study, the role of phosphorylation in the liquid-liquid phase separation (LLPS) of tau, the underlying driving forces, and the potential implications of this separation on protein conformation and subsequent protein aggregation were investigated. We compared in vivo-produced phosphorylated tau (p-tau) and nonphosphorylated tau under different coacervation conditions without adding crowding agents. Our findings revealed that spontaneous phase separation occurs exclusively in p-tau, triggered by a temperature shift from 4 °C to room temperature, and is driven by electrostatic and hydrophobic interactions.
View Article and Find Full Text PDFAtrial fibrillation development in the heart failure population from nationwide British linked electronic health records.
ESC Heart Fail
March 2025
Institute of Health Informatics Research, University College London, London, UK.
Aims: Atrial fibrillation (AF) is a frequent comorbidity in heart failure (HF). We analysed factors associated with new-onset atrial fibrillation in patients with heart failure using linked real-world UK data from primary and secondary care, along with findings from genome-wide association studies.
Methods And Results: Among 163 174 participants with a diagnosis of HF (January 1998 to May 2016) from Clinical Practice Research Datalink (CPRD) and Hospital Episodes Statistics (HES), 111 595 participants had no previous history of AF (mean age 76.
A 71-Year-Old Man With Gas Accumulation in the Left Atrium.
Chest
March 2025
Department of Intensive Care Medicine, Ningbo No.2 Hospital, Ningbo, Zhejiang, China.
A 71-year-old man with a history of atrial fibrillation presented to the emergency department with sudden unconsciousness after finishing lunch. Just 4 weeks ago, the patient underwent radiofrequency ablation for atrial fibrillation and regularly took rivaroxaban for anticoagulant therapy. According to the medical history, the patient suffered recurrent chest tightness and heartburn after radiofrequency ablation without other discomforts.
View Article and Find Full Text PDFDeveloping and Validating a New Atrial Fibrillation Risk Score Using Medical Examination Items in a Japanese Population - The Suita Study.
Circ J
March 2025
Department of Preventive Cardiology, National Cerebral and Cardiovascular Center.
Background: The aim of this was to develop an atrial fibrillation (AF) risk score using items usually included in Japanese governmental health check-ups.
Methods And Results: We analyzed data from 6,476 Japanese participants registered in the Suita Study. At baseline, the participants were aged ≥30 years and were free from AF.
Transcatheter aortic valve implantation versus surgical aortic valve replacement in patients at lower surgical risk: meta-analysis of randomized trials.
Can J Cardiol
March 2025
Department of Cardiology, Rabin Medical Center, Petah Tikva, Israel; The Faculty of Medicine, Tel Aviv University, Tel Aviv, Israel.
Background: The use of transcatheter aortic valve implantation (TAVI) for severe aortic stenosis is expanding to patients across the entire spectrum of surgical risk. We aimed to perform a meta-analysis comparing TAVI and surgical aortic valve replacement (SAVR) in trials enrolling lower risk patients.
Methods: We conducted a meta-analysis of randomized controlled trials (RCTs) comparing safety and efficacy outcomes between TAVI and SAVR among lower risk patients (mean/median STS score <4).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!